Base de dados : MEDLINE
Pesquisa : D12.644.276.374.465.516 [Categoria DeCS]
Referências encontradas : 503 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 51 ir para página                         

  1 / 503 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28423581
[Au] Autor:Smith EA; Kumar B; Komurov K; Smith SM; Brown NV; Zhao S; Kumar P; Teknos TN; Wells SI
[Ad] Endereço:Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
[Ti] Título:DEK associates with tumor stage and outcome in HPV16 positive oropharyngeal squamous cell carcinoma.
[So] Source:Oncotarget;8(14):23414-23426, 2017 Apr 04.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Oropharyngeal squamous cell carcinomas (OPSCC) are common, have poor outcomes, and comprise two biologically and clinically distinct diseases. While OPSCC that arise from human papillomavirus infections (HPV+) have better overall survival than their HPV- counterparts, the incidence of HPV+ OPSCC is increasing dramatically, affecting younger individuals which are often left with life-long co-morbidities from aggressive treatment. To identify patients which do poorly versus those who might benefit from milder regimens, risk-stratifying biomarkers are now needed within this population. One potential marker is the DEK oncoprotein, whose transcriptional upregulation in most malignancies is associated with chemotherapy resistance, advanced tumor stage, and worse outcomes. Herein, a retrospective case study was performed on DEK protein expression in therapy-naïve surgical resections from 194 OPSCC patients. We found that DEK was associated with advanced tumor stage, increased hazard of death, and interleukin IL6 expression in HPV16+ disease. Surprisingly, DEK levels in HPV16- OPSCC were not associated with advanced tumor stage or increased hazard of death. Overall, these findings mark HPV16- OPSCC as an exceptional malignancy were DEK expression does not correlate with outcome, and support the potential prognostic utility of DEK to identify aggressive HPV16+ disease.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/metabolismo
Proteínas Cromossômicas não Histona/metabolismo
Proteínas Oncogênicas/metabolismo
Neoplasias Orofaríngeas/metabolismo
Infecções por Papillomavirus/metabolismo
[Mh] Termos MeSH secundário: Idoso
Biomarcadores Tumorais/metabolismo
Carcinoma de Células Escamosas/complicações
Carcinoma de Células Escamosas/cirurgia
Inibidor p16 de Quinase Dependente de Ciclina/metabolismo
Feminino
Papillomavirus Humano 16/fisiologia
Seres Humanos
Imuno-Histoquímica
Interleucina-16/metabolismo
Masculino
Meia-Idade
Estadiamento de Neoplasias
Neoplasias Orofaríngeas/complicações
Neoplasias Orofaríngeas/cirurgia
Avaliação de Resultados (Cuidados de Saúde)/métodos
Avaliação de Resultados (Cuidados de Saúde)/estatística & dados numéricos
Infecções por Papillomavirus/complicações
Infecções por Papillomavirus/virologia
Proteínas de Ligação a Poli-ADP-Ribose
Prognóstico
Modelos de Riscos Proporcionais
Estudos Retrospectivos
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Chromosomal Proteins, Non-Histone); 0 (Cyclin-Dependent Kinase Inhibitor p16); 0 (Dek protein, human); 0 (Interleukin-16); 0 (Oncogene Proteins); 0 (Poly-ADP-Ribose Binding Proteins)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15582


  2 / 503 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28186695
[Au] Autor:Zheng W; Lu Y; Lin S; Wang R; Qiu L; Zhu Y; Yao B; Guo F; Jin S; Jin L; Li Y
[Ad] Endereço:State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Innovation Center for Cell Signaling Network, Xiamen University, Xiamen, Fujian, 361005, China.
[Ti] Título:A Novel Class of Natural FXR Modulators with a Unique Mode of Selective Co-regulator Assembly.
[So] Source:Chembiochem;18(8):721-725, 2017 Apr 18.
[Is] ISSN:1439-7633
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The farnesoid X receptor (FXR) is an important target for drug discovery. Small molecules induce a conformational change in FXR that modulates its binding to co-regulators, thus resulting in distinct FXR functional profiles. However, the mechanisms for selectively recruiting co-regulators by FXR remain elusive, partly because of the lack of FXR-selective modulators. We report the identification of two natural terpenoids, tschimgine and feroline, as novel FXR modulators. Remarkably, their crystal structures uncovered a secondary binding pocket important for ligand binding. Further, tschimgine or feroline induced dynamic conformational changes in the activation function 2 (AF-2) surface, thus leading to differential co-regulator recruiting profiles, modulated by both hydrophobic and selective hydrogen-bond interactions unique to specific co-regulators. Our findings thus provide a novel structure template for optimization for FXR-selective modulators of clinical value.
[Mh] Termos MeSH primário: Compostos Bicíclicos com Pontes/farmacologia
Ciclodecanos/farmacologia
Hidroxibenzoatos/farmacologia
Parabenos/farmacologia
Receptores Citoplasmáticos e Nucleares/agonistas
[Mh] Termos MeSH secundário: Animais
Sítios de Ligação
Haplorrinos
Células Hep G2
Seres Humanos
Interleucina-16/metabolismo
Ligantes
Óxido Nítrico Sintase Tipo II/metabolismo
Mutação Puntual
Estrutura Terciária de Proteína
Receptores Citoplasmáticos e Nucleares/química
Receptores Citoplasmáticos e Nucleares/genética
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bridged Bicyclo Compounds); 0 (Cyclodecanes); 0 (Hydroxybenzoates); 0 (Interleukin-16); 0 (Ligands); 0 (Parabens); 0 (Receptors, Cytoplasmic and Nuclear); 0 (Tumor Necrosis Factor-alpha); 0 (farnesoid X-activated receptor); 0 (feroline); 38970-50-2 (tschimgin); EC 1.14.13.39 (NOS2 protein, human); EC 1.14.13.39 (Nitric Oxide Synthase Type II)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE
[do] DOI:10.1002/cbic.201700059


  3 / 503 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28167650
[Au] Autor:Rider P; Voronov E; Dinarello CA; Apte RN; Cohen I
[Ad] Endereço:Department of Clinical Biochemistry and Pharmacology, Ben Gurion University of the Negev, 84105 Beer-Sheva, Israel.
[Ti] Título:Alarmins: Feel the Stress.
[So] Source:J Immunol;198(4):1395-1402, 2017 Feb 15.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Over the last decade, danger-associated molecular pattern molecules, or alarmins, have been recognized as signaling mediators of sterile inflammatory responses after trauma and injury. In contrast with the accepted passive release models suggested by the "danger hypothesis," it was recently shown that alarmins can also directly sense and report damage by signaling to the environment when released from live cells undergoing physiological stress, even without loss of subcellular compartmentalization. In this article, we review the involvement of alarmins such as IL-1α, IL-33, IL-16, and high-mobility group box 1 in cellular and physiological stress, and suggest a novel activity of these molecules as central initiators of sterile inflammation in response to nonlethal stress, a function we denote "stressorins." We highlight the role of posttranslational modifications of stressorins as key regulators of their activity and propose that targeted inhibition of stressorins or their modifiers could serve as attractive new anti-inflammatory treatments for a broad range of diseases.
[Mh] Termos MeSH primário: Alarminas/fisiologia
Estresse Fisiológico
[Mh] Termos MeSH secundário: Animais
Proteína HMGB1/metabolismo
Seres Humanos
Inflamação
Interleucina-16/metabolismo
Interleucina-1alfa/metabolismo
Interleucina-33/metabolismo
Camundongos
Processamento de Proteína Pós-Traducional
Estresse Fisiológico/imunologia
Estresse Fisiológico/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Alarmins); 0 (HMGB1 Protein); 0 (IL1A protein, human); 0 (IL33 protein, human); 0 (Interleukin-16); 0 (Interleukin-1alpha); 0 (Interleukin-33)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1601342


  4 / 503 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27986411
[Au] Autor:Teran LM; Ramirez-Jimenez F; Soid-Raggi G; Velazquez JR
[Ad] Endereço:Departamento de Inmunogenética y Alergia, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
[Ti] Título:Interleukin 16 and CCL17/thymus and activation-regulated chemokine in patients with aspirin-exacerbated respiratory disease.
[So] Source:Ann Allergy Asthma Immunol;118(2):191-196, 2017 Feb.
[Is] ISSN:1534-4436
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Interleukin (IL) 16 and thymus and activation-regulated cytokine (TARC) are chemoattractant cytokines for eosinophils and T 2 cells. Differential levels of these components in aspirin-exacerbated respiratory disease (AERD) and allergic rhinitis with asthma (ARwA) may be related to a different inflammatory response in both asthma phenotypes. OBJECTIVE: To assess the nasal lavage immunoreactivity of IL-16 and TARC cytokines. METHODS: We used multienzyme-linked immunosorbent assays to detect IL-5, IL-13, IL-16, IL-33, I-309/CCL1, TARC/CCL17, monocyte-derived chemokine/CCL22, periostin, and eosinophil cationic protein levels in nasal lavages from patients with AERD and patients with ARwA. RESULTS: The IL-13, IL-16, TARC, and periostin levels were significantly higher in patients with AERD compared with those of patients with ARwA. Correlation analysis of mediator levels in AERD revealed a possible role of IL-16 and TARC in eosinophil recruitment and activation. CONCLUSION: IL-16, TARC, and periostin distinguish between patients with AERD and those with ARwA. These mediators, taken together rather than individually, may comprise good specific nasal markers in patients with AERD. The effects of IL-16 and TARC on T 1, T 2, and T-regulatory cell functions in AERD cannot be disregarded.
[Mh] Termos MeSH primário: Aspirina/efeitos adversos
Quimiocina CCL17/metabolismo
Hipersensibilidade a Drogas/etiologia
Hipersensibilidade a Drogas/metabolismo
Interleucina-16/metabolismo
Hipersensibilidade Respiratória/etiologia
Hipersensibilidade Respiratória/metabolismo
[Mh] Termos MeSH secundário: Adulto
Biomarcadores
Hipersensibilidade a Drogas/diagnóstico
Eosinófilos/imunologia
Eosinófilos/metabolismo
Feminino
Seres Humanos
Imunoglobulina E/sangue
Imunoglobulina E/imunologia
Masculino
Meia-Idade
Líquido da Lavagem Nasal/imunologia
Fenótipo
Testes de Função Respiratória
Hipersensibilidade Respiratória/diagnóstico
Testes Cutâneos
Células Th2/imunologia
Células Th2/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Chemokine CCL17); 0 (Interleukin-16); 37341-29-0 (Immunoglobulin E); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161218
[St] Status:MEDLINE


  5 / 503 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27832278
[Au] Autor:Fang S; Huang Y; Zhong S; Zhang Y; Liu X; Wang Y; Gu P; Zhou H; Fan X
[Ad] Endereço:Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai.
[Ti] Título:IL-17A Promotes RANTES Expression, But Not IL-16, in Orbital Fibroblasts Via CD40-CD40L Combination in Thyroid-Associated Ophthalmopathy.
[So] Source:Invest Ophthalmol Vis Sci;57(14):6123-6133, 2016 Nov 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: This present study aims to investigate the phenotype of IL-17A-producing T cells in thyroid-associated ophthalmopathy (TAO) and the role of IL-17A on RANTES and IL-16 expression in orbital fibroblasts (OFs) from TAO patients. Methods: Blood samples were obtained from TAO patients and healthy controls and were subjected to ELISA and flow cytometry analysis. Primary human OFs cultured from surgical wastes were stimulated with IL-17A in the presence or absence of CD40L and were examined by qRT-PCR, ELISA, Western blotting, and apoptosis assays. Results: We reported upregulated IL-17A, IFN-γ, RANTES, and IL-16 serum levels and increased frequency of IL-17A- and IFN-γ-producing T cells in peripheral blood mononuclear cells from patients with TAO compared with healthy controls. In addition, TAO orbital tissues were rich in T lymphocytes, expressing more IL-17A, IFN-γ, RANTES, and IL-16. Moreover, IL-17A could enhance the expression of RANTES, but not IL-16, in cultured primary OFs in cooperation with CD40L. We further validated that MAPK signaling was largely responsible for RANTES production in IL-17A-treated OFs. Finally, we demonstrated that IL-17A could not promote apparent apoptosis in OFs from TAO patients and healthy controls. Conclusions: Our results indicate the potent effect of IL-17A-induced RANTES expression on OFs and elaborate a possible mechanism in understanding Th17 cells in the pathology of TAO and its potential as a target to immunotherapy of TAO and other autoimmune disorders.
[Mh] Termos MeSH primário: Antígenos CD40/metabolismo
Ligante de CD40/metabolismo
Quimiocina CCL5/genética
Regulação da Expressão Gênica
Oftalmopatia de Graves/genética
Interleucina-17/genética
RNA Mensageiro/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Western Blotting
Células Cultivadas
Quimiocina CCL5/biossíntese
Ensaio de Imunoadsorção Enzimática
Feminino
Fibroblastos/metabolismo
Fibroblastos/patologia
Citometria de Fluxo
Oftalmopatia de Graves/diagnóstico
Oftalmopatia de Graves/metabolismo
Seres Humanos
Interleucina-16/biossíntese
Interleucina-16/genética
Interleucina-17/biossíntese
Masculino
Meia-Idade
Órbita/patologia
Reação em Cadeia da Polimerase em Tempo Real
Transdução de Sinais
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CD40 Antigens); 0 (Chemokine CCL5); 0 (IL17A protein, human); 0 (Interleukin-16); 0 (Interleukin-17); 0 (RNA, Messenger); 147205-72-9 (CD40 Ligand)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161111
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.16-20199


  6 / 503 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27799724
[Au] Autor:Radulescu C; Bacârea A; HuÈ›anu A; Gabor R; Dobreanu M
[Ad] Endereço:Department of Obstetrics and Gynecology II, University of Medicine and Pharmacy of Tîrgu MureÈ™, Târgu MureÈ™, Romania.
[Ti] Título:Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia.
[So] Source:Mediators Inflamm;2016:3027363, 2016.
[Is] ISSN:1466-1861
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Preeclampsia (PE), an important cause of maternal and perinatal morbidity and mortality worldwide, is a pregnancy-related disease characterized by hypertension and proteinuria after 20 weeks of gestation. The aim of our study was to find a practical panel of biomarkers useful in early diagnosis of PE. This study was carried out at the Obstetrics and Gynecology Department in Tîrgu MureÈ™ University Hospital, Romania, between January 2014 and July 2015 and included 68 pregnant women (47 preeclamptic women and 21 controls) with gestational age between 16 and 20 weeks at enrollment. The biomarkers PlGF, sFlt-1, sEng, IL-6, and IL-16 were determined by ELISA test. We compared the serum levels of soluble markers analysed in preeclamptic women and controls during the second and third trimesters of pregnancy and we found that the best predictor for PE was PlGF with a sensitivity of 100% at a concentration threshold of 120.16 pg/mL, a diagnosis accuracy of 70.8%, and AUC of 0.684 ( = 0.005). We also estimated the risk for PE according to BMI and we found that pregnant women with weight >90 kg had 7 times higher risk for PE. Second-trimester PlGF serum level may serve as an early biomarker for the diagnosis of PE.
[Mh] Termos MeSH primário: Biomarcadores/sangue
Endoglina/sangue
Interleucina-16/sangue
Interleucina-6/sangue
Fator de Crescimento Placentário/sangue
Pré-Eclâmpsia/sangue
Receptor 1 de Fatores de Crescimento do Endotélio Vascular/sangue
[Mh] Termos MeSH secundário: Adulto
Índice de Massa Corporal
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Gravidez
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Endoglin); 0 (Interleukin-16); 0 (Interleukin-6); 144589-93-5 (Placenta Growth Factor); EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161102
[St] Status:MEDLINE


  7 / 503 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27788245
[Au] Autor:Purzycka-Bohdan D; Szczerkowska-Dobosz A; Zablotna M; Wierzbicka J; Piotrowska A; Zmijewski MA; Nedoszytko B; Nowicki R
[Ad] Endereço:Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.
[Ti] Título:Assessment of Interleukin 16 Serum Levels and Skin Expression in Psoriasis Patients in Correlation with Clinical Severity of the Disease.
[So] Source:PLoS One;11(10):e0165577, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Interleukin 16 (IL-16) has been described as a significant cytokine involved in the recruitment of CD4+ cells during inflammation; however, its potential role in psoriasis has not been defined. Our aim was to investigate the IL-16 serum levels and IL-16 mRNA skin expression in psoriasis patients in correlation with disease severity and mRNA skin expression for CD4. Moreover, the IL-16 skin localization was assessed and the -295 T/C IL-16 polymorphism was analyzed. For this exploratory, observational, and cross-sectional study, 97 unrelated patients with chronic plaque type psoriasis and 104 healthy controls were enrolled. IL-16 serum levels were significantly increased in patients compared with controls (P = 0.000022) and positively correlated with Psoriasis Area and Severity Index (r = 0.34, P = 0.0007), Body Surface Area (r = 0.34, P = 0.01) and were significantly higher in individuals with moderate to severe psoriasis (P = 0.0029). There was no significant correlation between IL-16 serum levels and Dermatology Quality of Life Index and no differences in genotype and allele frequencies for -295 T/C IL-16 polymorphism. The expression of IL-16 (mRNA and protein) was elevated in the margin of psoriatic skin while statistically significant increase in IL-16 immunoreactivity, but not in mRNA level, was observed within plaques. Furthermore, the IL-16 mRNA levels within psoriatic lesions positively correlated with the levels of CD4 mRNA, but not with Psoriasis Area and Severity Index. In conclusion, our data revealed an association between circulating IL-16 and severity of psoriasis which indicates that this cytokine could serve as a potential marker of disease activity. However, further investigations are required.
[Mh] Termos MeSH primário: Interleucina-16/metabolismo
Psoríase/patologia
Índice de Gravidade de Doença
Pele/metabolismo
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Biomarcadores/metabolismo
Estudos de Casos e Controles
Estudos Transversais
Seres Humanos
Interleucina-16/sangue
Interleucina-16/genética
Psoríase/sangue
RNA Mensageiro/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Interleukin-16); 0 (RNA, Messenger)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161028
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0165577


  8 / 503 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27695312
[Au] Autor:Andersson A; Malmhäll C; Houltz B; Tengvall S; Sjöstrand M; Qvarfordt I; Lindén A; Bossios A
[Ad] Endereço:Respiratory Medicine and Allergology, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
[Ti] Título:Interleukin-16-producing NK cells and T-cells in the blood of tobacco smokers with and without COPD.
[So] Source:Int J Chron Obstruct Pulmon Dis;11:2245-2258, 2016.
[Is] ISSN:1178-2005
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Long-term exposure to tobacco smoke causes local inflammation in the airways that involves not only innate immune cells, including NK cells, but also adaptive immune cells such as cytotoxic (CD8 ) and helper (CD4 ) T-cells. We have previously demonstrated that long-term tobacco smoking increases extracellular concentration of the CD4 -recruiting cytokine interleukin (IL)-16 locally in the airways. Here, we hypothesized that tobacco smoking alters IL-16 biology at the systemic level and that this effect involves oxygen free radicals (OFR). METHODS: We quantified extracellular IL-16 protein (ELISA) and intracellular IL-16 in NK cells, T-cells, B-cells, and monocytes (flow cytometry) in blood samples from long-term tobacco smokers with and without chronic obstructive pulmonary disease (COPD) and in never-smokers. NK cells from healthy blood donors were stimulated with water-soluble tobacco smoke components (cigarette smoke extract) with or without an OFR scavenger (glutathione) in vitro and followed by quantification of IL-16 protein. RESULTS: The extracellular concentrations of IL-16 protein in blood did not display any substantial differences between groups. Notably, intracellular IL-16 protein was detected in all types of blood leukocytes. All long-term smokers displayed a decrease in this IL-16 among NK cells, irrespective of COPD status. Further, both NK and CD4 T-cell concentrations displayed a negative correlation with pack-years. Moreover, cigarette smoke extract caused release of IL-16 protein from NK cells in vitro, and this was not affected by glutathione, in contrast to the decrease in intracellular IL-16, which was prevented by this drug. CONCLUSION: Long-term exposure to tobacco smoke does not markedly alter extracellular concentrations of IL-16 protein in blood. However, it does decrease the intracellular IL-16 concentrations in blood NK cells, the latter effect involving OFR. Thus, long-term tobacco smoking exerts an impact at the systemic level that involves NK cells; innate immune cells that are critical for host defense against viruses and tumors - conditions that are overrepresented among smokers.
[Mh] Termos MeSH primário: Mediadores da Inflamação/sangue
Interleucina-16/sangue
Células Matadoras Naturais/imunologia
Doença Pulmonar Obstrutiva Crônica/imunologia
Fumar/imunologia
Subpopulações de Linfócitos T/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Antioxidantes/farmacologia
Linfócitos B/imunologia
Estudos de Casos e Controles
Separação Celular/métodos
Células Cultivadas
Ensaio de Imunoadsorção Enzimática
Feminino
Citometria de Fluxo
Glutationa/farmacologia
Seres Humanos
Interferon gama/metabolismo
Células Matadoras Naturais/efeitos dos fármacos
Células Matadoras Naturais/metabolismo
Masculino
Meia-Idade
Monócitos/imunologia
Estresse Oxidativo/efeitos dos fármacos
Doença Pulmonar Obstrutiva Crônica/sangue
Doença Pulmonar Obstrutiva Crônica/diagnóstico
Doença Pulmonar Obstrutiva Crônica/etiologia
Espécies Reativas de Oxigênio/metabolismo
Fumaça/efeitos adversos
Fumar/efeitos adversos
Fumar/sangue
Subpopulações de Linfócitos T/efeitos dos fármacos
Subpopulações de Linfócitos T/metabolismo
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (IFNG protein, human); 0 (Inflammation Mediators); 0 (Interleukin-16); 0 (Reactive Oxygen Species); 0 (Smoke); 82115-62-6 (Interferon-gamma); GAN16C9B8O (Glutathione)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161004
[St] Status:MEDLINE


  9 / 503 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
PubMed Central Texto completo
Texto completo
[PMID]:27366013
[Au] Autor:Yoon CH; Lee HJ; Lee EY; Lee EB; Lee WW; Kim MK; Wee WR
[Ad] Endereço:Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.; Laboraory of Ocular Regenerative Medicine and Immunology, Artificial Eye Center, Seoul National University Hospital Biomedical Research Institute, Seoul, Korea.
[Ti] Título:Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.
[So] Source:J Korean Med Sci;31(7):1127-35, 2016 Jul.
[Is] ISSN:1598-6357
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:The effect of hydroxychloroquine (HCQ) on dry eye has not been fully determined. This study aimed to compare the 12-week efficacy of HCQ medication with that of a placebo in the management of dry eye in primary Sjögren's syndrome (pSS). A double-blind, randomized control study was conducted in 39 pSS subjects from May 2011 through August 2013. pSS was diagnosed based on the classification criteria of the American-European Consensus Group. Subjects received 300 mg of HCQ or placebo once daily for 12 weeks and were evaluated at baseline, 6, and 12 weeks, with a re-visit at 16 weeks after drug discontinuance. The fluorescein staining score, Schirmer test score, tear film break-up time (TBUT), and ocular surface disease index (OSDI) were measured, and tears and blood were collected for ESR, IL-6, IL-17, B-cell activating factor (BAFF), and Th17 cell analysis. Color testing was performed and the fundus was examined to monitor HCQ complications. Twenty-six subjects completed the follow-up. The fluorescein staining score and Schirmer test score did not differ significantly. The OSDI improved with medication in the HCQ group but was not significantly different between the groups. TBUT, serum IL-6, ESR, serum and tear BAFF, and the proportion of Th17 cells did not change in either group. HCQ at 300 mg daily for 12 weeks has no apparent clinical benefit for dry eye and systemic inflammation in pSS (ClinicalTrials.gov. NCT01601028).
[Mh] Termos MeSH primário: Síndromes do Olho Seco/tratamento farmacológico
Hidroxicloroquina/uso terapêutico
Síndrome de Sjogren/complicações
[Mh] Termos MeSH secundário: Idoso
Fator Ativador de Células B/análise
Fator Ativador de Células B/sangue
Sedimentação Sanguínea
Método Duplo-Cego
Esquema de Medicação
Síndromes do Olho Seco/complicações
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Interleucina-16/análise
Interleucina-16/sangue
Interleucina-17/análise
Interleucina-17/sangue
Masculino
Meia-Idade
Efeito Placebo
Estudos Prospectivos
Síndrome de Sjogren/diagnóstico
Células Th17/citologia
Células Th17/imunologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (B-Cell Activating Factor); 0 (Interleukin-16); 0 (Interleukin-17); 4QWG6N8QKH (Hydroxychloroquine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170410
[Lr] Data última revisão:
170410
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160702
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.3346/jkms.2016.31.7.1127


  10 / 503 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27323152
[Au] Autor:Yang SX; Chen F; Zhang JW; Sun ZQ; Chen BP
[Ad] Endereço:Department of Nephrology, Huaihe Hospital of Henan University, Kaifeng, Henan, China.
[Ti] Título:IL-16 rs4778889 polymorphism contribution to the development of renal cell cancer in a Chinese population.
[So] Source:Genet Mol Res;15(2), 2016 Jun 10.
[Is] ISSN:1676-5680
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:IL-16 plays an important role in affect the secretion of tumor-related inflammatory cytokines. We aimed to assess the role of interleukin-16 (IL-16) rs4778889 T/C and rs11556218 T/G polymorphisms in the occurrence of renal cell cancer (RCC). This study is composed of 274 RCC patients and 274 control subjects. Genotyping of polymorphisms was performed using polymerase chain reaction combined with restriction fragment length polymorphism analysis. All statistical analysis was carried out by the SPSS statistical software package, version 16.0 (SPSS Inc., Chicago, IL, USA). Using conditional logistic regression analysis, the TC and CC genotypes of rs4778889 exhibited a higher risk of RCC, with adjusted ORs (and 95%CIs) of 1.79 (1.23-2.62) and 2.67 (1.29-5.69), respectively. Moreover, under dominant and recessive models, individuals carried the rs4778889 polymorphism was exhibited elevated RCC risk, with adjusted ORs (and 95%CI) of 1.93 (1.35-2.76) and 2.11 (1.05-4.45), respectively. No significant differences were observed in rs11556218 genotype frequencies between the study groups. In conclusion, the results of our study reveal an association between the IL-16 rs4778889 polymorphism and heightened risk of RCC.
[Mh] Termos MeSH primário: Carcinoma de Células Renais/genética
Estudos de Associação Genética
Predisposição Genética para Doença
Interleucina-16/genética
[Mh] Termos MeSH secundário: Idoso
Grupo com Ancestrais do Continente Asiático
Carcinoma de Células Renais/patologia
Feminino
Genótipo
Seres Humanos
Masculino
Meia-Idade
Polimorfismo de Fragmento de Restrição
Polimorfismo de Nucleotídeo Único
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Interleukin-16)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170208
[Lr] Data última revisão:
170208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160621
[St] Status:MEDLINE
[do] DOI:10.4238/gmr.15027553



página 1 de 51 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde